, Volume 27, Issue 1, pp 57–66 | Cite as

IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients

  • Yufang Liu
  • Guifang Qin
  • Zudong MengEmail author
  • Tianping Du
  • Xiaolan Wang
  • Yong Tang
  • Jingjing Cao
Original Article



This study aimed to explore the correlation of circulating inflammatory cytokines’ levels with treatment response to etanercept (ETN) treatment in psoriasis patients.


97 moderate-to-severe plaque-psoriasis patients were continuously recruited in this prospective cohort study, and all patients received ETN treatment. Serum samples were collected before and at 6 months (M6) after treatment, and nine inflammatory cytokines expressions were detected by enzyme-linked immuno sorbent assay. Psoriasis Area and Severity Index (PASI) score was evaluated at baseline (M0), 1 month (M1), 3 months (M3) and M6 after treatment, and the corresponding PASI 75/90 responses’ rates were calculated.


Tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-12, IL-17A, IL-22, IL-23, and IL-32 levels were reduced, while IL-10 level was elevated at M6 after ETN treatment compared to baseline. PASI 75/90 responses’ rates to ETN were 69.1 and 38.1% at M6, respectively. IL-1β and IL-17A levels were elevated in PASI 75-response patients compared to PASI 75 non-response patients, while IL-17A level was also increased in PASI 90-response patients compared to PASI 90 non-response patients. Multivariate logistic regression revealed that IL-1β, IL-17A and combined phototherapy during study predicted higher, while previous systemic biologic treatment predicted lower PASI 75 response to ETN independently. In addition, IL-17A independently predicted higher PASI 90 response to ETN as well.


IL-1β, IL-17A, and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to ETN independently in psoriasis patients.


Inflammatory cytokines Psoriasis Treatment response PASI score 


Compliance with ethical standards

Conflict of interest

The authors declared that they have no conflict of interest.


  1. Boehncke WH, Schon MP (2015) Psoriasis. Lancet 386:983–994. CrossRefGoogle Scholar
  2. Carrascosa JM, Rebollo F, Gomez S, De-la-Cueva P (2018) Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. J Dermatol Treat. Google Scholar
  3. Di Lernia V et al (2018) Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatol Treat 29:217–219. CrossRefGoogle Scholar
  4. Fitz L et al (2018) Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis. Clin Exp Dermatol. Google Scholar
  5. Kanelleas A et al (2011) The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol 36:845–850. CrossRefGoogle Scholar
  6. Kivelevitch D, Mansouri B, Menter A (2014) Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics 8:169–182. Google Scholar
  7. Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. Google Scholar
  8. Motolese A, Chiaravalloti V, Cerati M, Oldrini R, Mola F, Passi A (2017) Interleukin levels and macrophagic density in periumbilical fat tissue in patients affected by moderate-to-severe psoriasis with metabolic syndrome, before and after etanercept treatment. G Ital Dermatol Venereol 152:342–347. Google Scholar
  9. Nakajima H, Nakajima K, Tarutani M, Morishige R, Sano S (2011) Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res 303:451–455. CrossRefGoogle Scholar
  10. Paller AS et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241–251. CrossRefGoogle Scholar
  11. Prinz JC, Puig L, Girolomoni G (2016) Treatment of psoriasis with etanercept: the typical patient profile. J Eur Acad Dermatol Venereol JEADV 30:1092–1099. CrossRefGoogle Scholar
  12. Senra L, Stalder R, Alvarez Martinez D, Chizzolini C, Boehncke WH, Brembilla NC (2016) Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J Invest Dermatol 136:1970–1980. CrossRefGoogle Scholar
  13. Shi R, Chen M, Litifu B (2018) Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol 28:126–132. CrossRefGoogle Scholar
  14. Sobhan MR, Farshchian M, Hoseinzadeh A, Ghasemibasir HR, Solgi G (2016) Serum levels of IL-10 and IL-22 cytokines in patients with psoriasis. Iran J Immunol 13(3):317–323Google Scholar
  15. Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L, Kuhn M, Fraser S (2017) Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin. AAPS J 19:1218–1222. CrossRefGoogle Scholar
  16. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 159:322–330. CrossRefGoogle Scholar
  17. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H (2010) Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 35:645–649. CrossRefGoogle Scholar
  18. Tan JK, Aphale A, Malaviya R, Sun Y, Gottlieb AB (2007) Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 12:38–45. CrossRefGoogle Scholar
  19. Tsai YC, Tsai TF (2017) Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis 9:277–294. CrossRefGoogle Scholar
  20. Wang F et al (2012) Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol 167:92–102. CrossRefGoogle Scholar
  21. Wasilewska A, Winiarska M, Olszewska M, Rudnicka L (2016) Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol 33:247–252. CrossRefGoogle Scholar
  22. Wolk K et al (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36:1309–1323. CrossRefGoogle Scholar
  23. Xie F et al (2017) Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. J Huazhong Univ Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban 37:943–947. Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Dermatology, The People’s Hospital of Shiyan, The Affiliated People’s HospitalHubei University of MedicineShiyanChina
  2. 2.Department of Neurosurgery, The People’s Hospital of Shiyan, The Affiliated People’s HospitalHubei University of MedicineShiyanChina
  3. 3.Department of Rehabilitation, Sinopharm Dong Feng General Hospital, The Affiliated Dong Feng HospitalHubei University of MedicineShiyanChina

Personalised recommendations